Tidal ETF Trust II YieldMax META Option Income Strategy ETF (ARCA: FBY)

Ultime notizie per Tidal ETF Trust II YieldMax META Option Income Strategy ETF (ARCA:FBY)

The Fund is an actively managed exchange-traded fund (ETF) that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of Meta Platforms, Inc. (META), subject to a limit on potential investment gains. The Fund will seek to employ its investment strategy as it relates to META regardless of whether there are periods adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods.

First American Government Obligations Fund

YieldMax META Option Income Strategy ETF

Tidal ETF Trust II YieldMax META Option Income Strategy ETF

Falcon's Beyond Global, Inc. - Class A Common Stock

Falcons Beyond Global Inc

FALCONS BEYOND GLOBAL INC PFD SER A 8%

UBS analyst Manav Gupta downgrades Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) from Buy to Neutral and raises the price target from $14 to $18.

News

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Venture Global to Neutral, Raises Price Target to $18

<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="500" height="281" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11201223/Two-Subways.jpg" alt="" class="wp-image-14303" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11201223/Two-Subways.jpg 500w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11201223/Two-Subways-300x169.jpg 300w" sizes="(max-width: 500px) 100vw, 500px" /></figure>
<h3 class="wp-block-heading">A Tale of Two Subway Stations</h3>
Clips of grimy New York platforms versus sleek Moscow or Shanghai stations highlight capacity to deliver public goods rather than mere aesthetics. They hint at structural problems that precede—and ultimately produce—America's $34 trillion federal debt.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Problem #1: Resources Flow to Low‑Productivity Services</h3>
The care‑giving boom in New York City
<ul class="wp-block-list">
<li>Between 2018 and mid‑2023, service hours in New York's&nbsp;<a href="https://www.health.ny.gov/health_care/medicaid/program/longterm/cdpap/">Consumer‑Directed Personal Assistance Program (CDPAP)</a>&nbsp;more than doubled, even as traditional agency hours fell 19%.&nbsp;This is a program that basically pays people $20 to $28 per hour to do errands for their elderly relatives—in some cases, on a fulltime basis..</li>
<li>CDPAP wages now account for roughly&nbsp;one in eight&nbsp;private‑sector paychecks in NYC.</li>
<li>Home‑health jobs grew by 57 k last year (≈10 %).</li>
<li>Medicaid reimburses most of those wages, so the dollars come from federal borrowing, yet the output shows up mostly as consumption—not&nbsp;capital formation.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Problem #2: Tradables Hollow‑Out</h3>
<ul class="wp-block-list">
<li>Tradables share of 2023 GDP (manufacturing + mining/drilling + agriculture): 
<ul class="wp-block-list">
<li>• United States ≈ 19 % • China ≈ 46 % • Russia ≈ 37 %</li>
</ul>
</li>
<li>Trade balance, 2023: • United States:&nbsp;−$1.1 T&nbsp;goods &amp; services deficit • China:&nbsp;+$800 B&nbsp;surplus • Russia:&nbsp;+$235 B&nbsp;surplus</li>
<li>The U.S. goods‑and‑services gap widened to&nbsp;$140 B in March 2025, the largest monthly shortfall on record.</li>
<li>Borrowing to fund imported tradables is a double drag: it swells federal debt&nbsp;and&nbsp;diverts purchasing power abroad instead of into domestic plant, equipment, and infrastructure.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Problem #3: Cost Disease in Public Works</h3>
Where did the $1.2 T Infrastructure Bill money go?
<ul class="wp-block-list">
<li>Two‑plus years after passage, most "projects" remain in design or permitting. DOE progress reports celebrate&nbsp;jobs created, not roads or bridges finished.</li>
<li>Francis Scott Key Bridge (Baltimore):&nbsp;struck in March 2024, geotech surveys began Jan 2025, full reopening&nbsp;target 2028.</li>
<li>Crimean Bridge (Russia):&nbsp;bombed Oct 2022, one lane reopened in 3 months, rail traffic restored in 9 months.</li>
<li>The contrast underscores America's permitting maze, fragmented ownership, and litigation risk that bloat costs and timelines.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Problem #4: Public‑Order Premium</h3>
<ul class="wp-block-list">
<li>Washington has floated tying transit grants to crime benchmarks, but accurate data went dark when the FBI's NIBRS rollout left 30 %+ of agencies unable to report.</li>
<li>Early 2025 DOJ guidance&nbsp;now requires agencies to file both legacy summary and NIBRS data until compliance tops 95 %, making performance‑tied funding viable—if Congress acts.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">How These Feed the Debt Loop</h3>
<ol class="wp-block-list">
<li>Low‑productivity domestic spending → weak real growth per borrowed dollar.</li>
<li>Trade‑deficit leakage → debt‑financed consumption instead of domestic investment.</li>
<li>High unit‑cost infrastructure → more borrowing for each unit of tangible capital.</li>
<li>Public‑order premium → higher operating costs and capital flight from cities.</li>
</ol>
Net interest is now the fastest‑growing budget line, crowding out discretionary investment while public spaces fray.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Partial Fixes Already in the&nbsp;One Big Beautiful Bill Act (OBBB)</h3>
<ul class="wp-block-list">
<li>The draft OBBB&nbsp;nods toward the right diagnosis—making bonus depreciation permanent (<a href="https://www.congress.gov/bill/119th-congress/house-bill/1?q=%7B%22search%22%3A%22%C2%A7111001%22%7D&amp;r=1&amp;s=2">§ 111001</a>) and tightening Medicaid attendant rules (<a href="https://www.congress.gov/bill/119th-congress/house-bill/1?q=%7B%22search%22%3A%22%C2%A7111001%22%7D&amp;r=1&amp;s=2">Subtitle E</a>)—but&nbsp;ducks&nbsp;the permitting morass and the accountability gap in transit funding. Until those last two are fixed, America will keep borrowing a premium price for sub‑premium public goods.</li>
<li>Missing:&nbsp;permitting reform and performance‑tied transit grants. Until those last two are fixed, America will keep borrowing premium dollars for sub‑premium public goods.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">What Would Treat the Disease, Not Just the Symptom</h3>
Raise tradables share
<ul class="wp-block-list">
<li>Neutral expensing for all structures.</li>
<li>Fast‑track energy‑intensive manufacturing permits.</li>
<li>Strategic tariffs / border adjustments—including the Trump Administration's 10 % baseline tariff on manufactured imports, the 60 % Section 301 duty on Chinese EVs, and a draft carbon border‑adjustment framework—to level the playing field.</li>
</ul>
Triage transfer programs
<ul class="wp-block-list">
<li>Sunset pass‑through home‑care models unless tied to measurable outcomes.</li>
<li>Re‑validate disability rolls.</li>
</ul>
Slash infrastructure unit‑costs
<ul class="wp-block-list">
<li>One‑agency permitting clock.</li>
<li>Benchmark budgets to OECD medians; claw back overruns.</li>
</ul>
Restore public order
<ul class="wp-block-list">
<li>Condition transit grants on crime‑rate benchmarks now that national data collection is back on track.</li>
</ul>
Restrict high‑corruption inflows
<ul class="wp-block-list">
<li>Tighten visa/green‑card issuance from nations scoring poorly on the Transparency International CPI, and ramp post‑arrival audits of federally reimbursed providers to curb Medicaid &amp; welfare fraud (e.g., the $1 B&nbsp;<a href="https://apnews.com/general-news-1bdca7b180a04449a2c86f99371fc5d0">Miami led by Cuban‑American physicians</a>&nbsp;and the Somali&nbsp;<a href="https://www.justice.gov/usao-mn/pr/three-plead-guilty-wire-fraud-250-million-feeding-our-future-fraud-scheme">$250 M &#8220;Feeding Our Future&#8221; scheme in Minnesota</a>.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Implications for Investors</h3>
<ul class="wp-block-list">
<li>Status‑quo trajectory (rising debt + financial repression):&nbsp;bitcoin‑proxy trades; gold and other hard‑asset hedges. We added to a position in one bitcoin proxy,&nbsp;Semler Scientific, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), yesterday. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/americas-debt-is-a-symptomnot-the"><img loading="lazy" decoding="async" width="882" height="597" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11201735/Trade-Alert-Bitcoin.jpg" alt="" class="wp-image-14304" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11201735/Trade-Alert-Bitcoin.jpg 882w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11201735/Trade-Alert-Bitcoin-300x203.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11201735/Trade-Alert-Bitcoin-768x520.jpg 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
<ul class="wp-block-list">
<li>Pivot to a more productive U.S. economy:&nbsp;new‑nuclear names, advanced‑manufacturing REITs, and on‑shoring enablers (chip‑fabrication equipment). We exited one new-nuclear name,&nbsp;Oklo, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), for a 385% gain last week. It was a Portfolio Armor top ten name last week as well, but I held off on putting a new trade on it, because I was concerned it had run too far. It's now up nearly 25% today, on news that it has been selected to supply power for a U.S. Air Force base in Alaska.</li>
</ul>
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/americas-debt-is-a-symptomnot-the"><img loading="lazy" decoding="async" width="880" height="597" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202013/Exits-6.6.jpg" alt="" class="wp-image-14305" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202013/Exits-6.6.jpg 880w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202013/Exits-6.6-300x204.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202013/Exits-6.6-768x521.jpg 768w" sizes="(max-width: 880px) 100vw, 880px" /></a></figure>
<ul class="wp-block-list">
<li>Holding both buckets lets a portfolio participate under either scenario.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Take‑away: Debt is the symptom, not the disease. Until the U.S. redirects capital from low‑yield consumption toward high‑yield production—and demands accountability for every infrastructure and safety dollar—borrowing will keep climbing no matter how loud the fiscal hawks squawk.
In the meantime, if you want to find Portfolio Armor's top names like Oklo, I post them in my weekly Top Names post.
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/top-names-652025"><img loading="lazy" decoding="async" width="916" height="812" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202202/Top-Names-6.5.jpg" alt="" class="wp-image-14306" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202202/Top-Names-6.5.jpg 916w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202202/Top-Names-6.5-300x266.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202202/Top-Names-6.5-768x681.jpg 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
You can also find them daily on the Portfolio Armor&nbsp;<a href="https://portfolioarmor.com/">website</a>&nbsp;and&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">iPhone app</a>.
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202334/PA-JPEG-1-1-1024x683.jpeg" alt="" class="wp-image-14307" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202334/PA-JPEG-1-1-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202334/PA-JPEG-1-1-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202334/PA-JPEG-1-1-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202334/PA-JPEG-1-1.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
And if you want a heads up when I place my next trade, you can subscribe to the Portfolio Armor Substack below. 
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202453/Widget-2.jpg" alt="" class="wp-image-14308" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202453/Widget-2.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/11202453/Widget-2-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Opinion

Trading Ideas

General

OKLO

SMLR

America's Debt Is a Symptom, Not the Disease: How Investors Can Position

B of A Securities analyst Brad Sills maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Neutral and raises the price target from $156 to $220.

ORCL

B of A Securities Maintains Neutral on Oracle, Raises Price Target to $220

Benchmark analyst Cody Acree reiterates ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) from Hold to Hold.

Reiteration

Benchmark Reiterates Hold on ARM Holdingsto Hold

WIIM

HSDT

Helius Medical Technologies shares are trading lower. The company announced PoNSTEP study results at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting.

B of A Securities analyst Bryan Spillane downgrades Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from Neutral to Underperform and lowers the price target from $27 to $20.

B of A Securities Downgrades Conagra Brands to Underperform, Lowers Price Target to $20

FTRE

Fortrea Board Adopts Limited-Duration Stockholder Rights Plan, Effective Immediately; Set To Expire June 10, 2026

Producer prices snapped back in May after an April decline, but the rebound fell short of sparking inflation concerns, suggesting tariffs and supply frictions have yet to bleed <a href="https://www.benzinga.com/news/econ-s">broadly into the economy.</a>
The Producer Price Index rose 2.6% on a year-over-year basis, up from April's upwardly revised 2.5%, according to Thursday's report from the Bureau of Labor Statistics. 
On a monthly basis, the PPI advanced 0.1%, reversing April's upwardly revised 0.2% decline, and below the 0.2% expected. 
Core PPI, which strips out food and energy prices and is a key indicator of underlying inflation pressures, eased to 3% annually from April's 3.2%. This marks the lowest level since August 2024. On a monthly basis, core PPI inched 0.1%, rebounding from a 0.2% decline in the prior month, below than expected 0.3%. 
Thursday's producer data arrived one day after a softer-than-expected consumer inflation reading. The Consumer Price Index climbed 2.4% year-over-year in May, up slightly from April's 2.3%, but below the anticipated 2.5% increase. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Producer Inflation</th>
<th>May 2025</th>
<th>April 2025</th>
<th>Expected</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPI YoY</td>
<td>2.6%</td>
<td>2.5%</td>
<td>2.6%</td>
</tr>
<tr>
<td>PPI MoM</td>
<td>0.1%</td>
<td>-0.2%</td>
<td>0.2%</td>
</tr>
<tr>
<td>Core PPI YoY</td>
<td>3.0%</td>
<td>3.2%</td>
<td>3.1%</td>
</tr>
<tr>
<td>Core PPI MoM</td>
<td>0.1%</td>
<td>-0.2%</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
</figure>
In a separate release Thursday, the Department of Labor reported that initial jobless claims rose to 248,000 for the week ending June 7, above forecasts for 240,000. Continuing claims surged to 1.956 million, the highest level since November 2021 and above consensus projections of 1.91 million.
The increase in unemployment filings is further evidence of a softening labor market, potentially giving the Federal Reserve additional room to resume the pace of interest rate cuts.
Fed futures currently price in a near-certainty of a first rate cut by October. Traders are assigning roughly 35 basis points of total easing by year-end, implying at least one full 25-basis-point cut and a high probability of a second.
This is a developing story&#8230;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45899819/us-stocks-likely-to-open-lower-look-through-near-term-noise-be-deliberate-about-the-kinds-of-risk-youre-taking-leverage-ai-say-experts">US Stocks Likely To Open Lower: &#8216;Look Through Near-Term Noise, Be Deliberate About The Kinds Of Risk You&#8217;re Taking, Leverage AI,&#8217; Say Experts</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Econ #s

Economics

Federal Reserve

Producer Inflation Rises Less Than Forecasts In May, Jobless Claims Signal Labor Market Cracks

INTS

Intensity Therapeutics shares are trading lower after the company announced it priced its $2 million public offering of 6.675 million shares at $0.30 per share

Stephens &amp; Co. analyst Jim Salera maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Equal-Weight and raises the price target from $178 to $200.

Stephens & Co. Maintains Equal-Weight on Darden Restaurants, Raises Price Target to $200

RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) will release earnings results for the first quarter, after the closing <a href="https://www.benzinga.com/quote/rh/earnings">bell on Thursday, June 12</a>.
Analysts expect the Corte Madera, California-based company to report quarterly loss at 7 cents per share, versus a year-ago loss of 40 cents per share. RH projects to report quarterly revenue at $818.57 million, compared to $726.96 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 20, RH named Lisa Chi as President and Co-Chief Merchandising &amp; Creative Officer.
RH shares fell 5.5% to close at $178.98 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/RH/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Zachary Fadem maintained an Overweight rating and cut the price target from $300 to $250 on June 9, 2025. This analyst has an accuracy rate of 84%.</li>
<li>UBS analyst Michael Lasser maintained a Neutral rating and cut the price target from $235 to $215 on June 5, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Goldman Sachs analyst Kate McShane maintained a Neutral rating and cut the price target from $276 to $194 on May 5, 2025. This analyst has an accuracy rate of 67%.</li>
<li>JP Morgan analyst Christopher Horvers maintained an Overweight rating and slashed the price target from $510 to $250 on April 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained an Overweight rating and cut the price target from $530 to $300 on April 3, 2025. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying RH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/RH/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179-1024x583.png" alt="" class="wp-image-947229" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Earnings

RH Likely To Report Narrower Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

As of June 12, 2025, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a> 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Caseys General Stores Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>)</h3>
<ul class="wp-block-list">
<li>On June 9, Caseys General Stores reported better-than-expected fourth-quarter financial results and increased its quarterly dividend. "Inside same-store sales outperformed the industry, up 2.6%, or 7.1% on a two-year stack basis, led by strong performance in hot sandwiches and bakery as well as alcoholic and non-alcoholic beverages. Our fuel team grew market share and produced a healthy margin, as fuel gross profit increased 10.7% from the prior year," said Darren Rebelez, president and CEO of Casey's General Stores. The company's stock jumped around 14% over the past month and has a 52-week high of $509.08.</li>
<li>RSI Value: 74.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CASY Price Action: Shares of Caseys General Stores gained 1.9% to close at $499.53 on Wednesday.</li>
<li>Edge Stock Ratings: 89.51 Momentum score with Value at 53.81. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/CASY"><img loading="lazy" decoding="async" width="436" height="197" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12072712/image-186.png" alt="" class="wp-image-947474" style="width:308px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12072712/image-186.png 436w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12072712/image-186-300x136.png 300w" sizes="(max-width: 436px) 100vw, 436px" /></a></figure>
<h3 class="wp-block-heading">elf Beauty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>)</h3>
<ul class="wp-block-list">
<li>On May 28, e.l.f. Beauty reported better-than-expected quarterly results and announced it will acquire Rhode. "In this dynamic environment, we continue to deliver industry-leading results. In Fiscal 2025, we grew net sales 28%, gained 190 basis points of market share in the U.S. and continued our international expansion strategy," said Tarang Amin, chairman and CEO of e.l.f. Beauty. The company's stock gained around 68% over the past month and <a href="https://www.benzinga.com/quote/ELF">has a 52-week high</a> of $219.77.</li>
<li>RSI Value: 88.1</li>
<li>ELF Price Action: Shares of elf Beauty gained 5.6% to close at $124.52 on Wednesday.</li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

CASY

Top 2 Defensive Stocks That May Keep You Up At Night In Q2

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Thursday.
Shares of Oxford Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) fell sharply in today's pre-market trading as the company reported in-line earnings for the first quarter and issued second-quarter earnings guidance below estimates. Also, the company <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45877826/oxford-industries-likely-to-report-lower-q1-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">lowered its FY25 guidance.</a>
Oxford Industries posted adjusted EPS of $1.82, in-line with estimates. The company's quarterly sales came in at $392.86 million versus expectations of $384.77 million.
Oxford Industries shares dipped 10.1% to $44.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) dipped 17% to $31.32 in pre-market trading. Tonix Pharmaceuticals may sell up to $150 million in common stock.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 12.4% to $24.97 in pre-market trading after the company announced a $1.75 billion proposed private offering of convertible senior notes.</li>
<li>Karooooo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) dipped 11.1% to $52.94 in pre-market trading.</li>
<li>Yiren Digital Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) declined 10.1% to $6.69 in pre-market trading.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 9.9% to $10.87 in pre-market trading.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 8.6% to $24.00 in pre-market trading.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 7.4% to $198.10 in pre-market trading. An Air India Boeing 787-8 Dreamliner by Boeing crashed on Thursday near the India's Ahmedabad airport, with 242 passengers on board. The flight was en route to London Gatwick from Ahmedabad.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) fell 4.4% to $234.57 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Movers

DFDV

KARO

TNXP

Oxford Industries, GameStop, Boeing And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care
HENDERSON, Nev., June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#NYSE">VNRX</a>) ("Volition"), a multi-national epigenetics company, today announced <a href="https://ccforum.biomedcentral.com/articles/10.1186/s13054-025-05415-6#citeas">the publication of a new clinical manuscript</a>&nbsp;suggesting that the Nu.Q&#xAE; H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment of sepsis, organ failure and subphenotypes.
About the Study This study aimed to evaluate H3.1 nucleosomes in critical illness, assessing their relationship with sepsis, organ failure, inflammatory subphenotypes and outcomes.
The MARS cohort was used, comprising of consecutive Intensive Care Unit patients (n=1713 patients), with plasma samples collected on days 0, 2 and 4 (n=3671 plasma samples).
H3.1 nucleosome concentrations were measured using the Nu.Q&#xAE; NETs Immunoassay at baseline and longitudinally.
The relationship between H3.1 nucleosome concentrations and clinical outcomes was investigated.

VNRX

VolitionRx Announces Publication Of New Clinical Manuscript Suggesting That Nu.Q H3.1 Biomarker Has Potential To Inform Clinical Care In Critically-Ill ICU Patients In Assessment Of Sepsis, Organ Failure And Subphenotypes

Contracts

Eaton Awarded Multiple Contracts Valued At $25M For Hartsfield-Jackson Atlanta International Airport

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Baird analyst David Manthey initiated coverage on QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) with an Outperform rating and announced a price target of $32. QXO shares closed at $19.95 on Wednesday. <a href="https://www.benzinga.com/quote/qxo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Yasmeen Rahimi initiated coverage on Tvardi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) with an Overweight rating and announced a price target of $78. Tvardi Therapeutics shares closed at $26.22 on Wednesday. <a href="https://www.benzinga.com/quote/tvrd/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth Capital analyst Joe Reagor initiated coverage on AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) with a Buy rating and announced a price target of $52. Anglogold Ashanti shares closed at $45.87 on Wednesday. <a href="https://www.benzinga.com/quote/AU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Texas Capital Securities analyst David Bain initiated coverage on Genius Sports Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Buy rating and announced a price target of $14. Genius Sports shares closed at $9.66 on Tuesday. <a href="https://www.benzinga.com/quote/GENI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst David Tarantino initiated coverage on Modine Manufacturing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) with an Overweight rating and announced a price target of $125. Modine Manufacturing shares closed at $94.15 on Wednesday. <a href="https://www.benzinga.com/quote/MOD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MOD stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Initiation

GENI

TVRD

This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Tempus AI To Collaborate With The Abrams Research Center On Neurogenomics At Northwestern University Feinberg School Of Medicine To Harness AI For Discovery in Alzheimer's Research

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announces that its Board of Directors have approved a proposed reverse stock split of its common stock at a ratio of 25-for-1. The proposed action remains subject to approval by Nasdaq and, if approved, the Company will issue a subsequent announcement disclosing the effective date.
At the effective time of the reverse stock split, every 25 shares of the Company's issued and outstanding common stock will be automatically reclassified and combined into 1 share of common stock. This will reduce the number of issued and outstanding shares of common stock from 26,210,037 shares to approximately 1,048,401 shares, without giving effect to rounding. The split will also apply to Company common stock issuable upon the exercise of the Company's outstanding RSU grants and warrants. No fractional shares will be issued; instead, any fractional entitlements will be rounded up to the next highest whole number at the participant level.
The reverse stock split is part of Shuttle's strategic plan to maintain compliance with Nasdaq's continued listing requirements, while also strengthening the Company's long-term capital structure.

Comments

Tidal ETF Trust II YieldMax META Option Income Strategy ETF

Notizie

Ultime notizie per Tidal ETF Trust II YieldMax META Option Income Strategy ETF (ARCA:FBY)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO